Hyperpolarized Xe129 ( DrugBank: - )
2 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
85 | 特発性間質性肺炎 | 1 |
299 | 嚢胞性線維症 | 1 |
85. 特発性間質性肺炎
臨床試験数 : 598 / 薬物数 : 435 - (DrugBank : 116) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 210
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04677426 (ClinicalTrials.gov) | January 1, 2022 | 16/12/2020 | 129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study | 129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study | Idiopathic Pulmonary Fibrosis;Hypersensitivity Pneumonitis | Drug: Hyperpolarized Xe129 | University of Kansas Medical Center | Duke University;Children's Hospital Medical Center, Cincinnati;Boehringer Ingelheim | Not yet recruiting | 18 Years | N/A | All | 40 | Phase 2 | NULL |
299. 嚢胞性線維症
臨床試験数 : 1,696 / 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04624490 (ClinicalTrials.gov) | November 2, 2020 | 31/10/2020 | Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease | Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease | Asthma;COPD;Interstitial Lung Disease;Cystic Fibrosis;Pulmonary Hypertension;Pulmonary Infection;Other Lung Disease | Drug: Hyperpolarized Xe129 | Mario Castro, MD, MPH | NULL | Recruiting | 3 Years | N/A | All | 260 | Phase 1 | United States |